Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) shares crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $5.53 and traded as high as $5.60. Seres Therapeutics shares last traded at $5.54, with a volume of 63,651 shares traded.
Analysts Set New Price Targets
A number of equities research analysts recently commented on MCRB shares. Weiss Ratings lowered Seres Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 11th. Zacks Research raised shares of Seres Therapeutics to a "hold" rating in a report on Tuesday, June 23rd. Wall Street Zen raised shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, HC Wainwright assumed coverage on Seres Therapeutics in a research report on Tuesday, June 23rd. They issued a "buy" rating and a $12.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $17.00.
View Our Latest Analysis on MCRB
Seres Therapeutics Price Performance
The firm has a market cap of $55.68 million, a PE ratio of -2.28 and a beta of 0.21. The stock's fifty day moving average price is $5.53 and its 200-day moving average price is $7.17.
Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of ($2.18) by $2.65. The company had revenue of $0.74 million during the quarter, compared to the consensus estimate of $0.18 million. Seres Therapeutics had a negative net margin of 1,192.94% and a negative return on equity of 114.82%. On average, sell-side analysts anticipate that Seres Therapeutics, Inc. will post -6.33 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Seres Therapeutics
Large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its position in shares of Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 21,679 shares in the last quarter. Invesco Ltd. lifted its position in Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 89,995 shares during the last quarter. Bank of America Corp DE grew its stake in Seres Therapeutics by 2,772.6% during the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company's stock worth $103,000 after buying an additional 5,157 shares during the last quarter. Barclays PLC increased its holdings in shares of Seres Therapeutics by 427.8% in the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company's stock valued at $111,000 after acquiring an additional 6,024 shares during the period. Finally, ExodusPoint Capital Management LP acquired a new position in Seres Therapeutics in the fourth quarter valued at $190,000. 59.34% of the stock is currently owned by institutional investors and hedge funds.
Seres Therapeutics Company Profile
(
Get Free Report)
Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company's approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.
Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
